Article
The Concept behind the Suitability of Menstrual Blood-Derived Stem Cells for the Management of Vaginal Atrophy among BRCA Mutation Carriers after RRSO.
International journal of molecular sciences - 14 Jan 2024
Cordeiro Mariana Robalo, Laranjeiro Bárbara, Figueiredo-Dias Margarida
Abstract excerpt
Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended for breast cancer gene 1 (BRCA1) and 2 (BRCA2) mutation carriers. A major consequence of RRSO is surgical menopause associated with severe menopausal symptoms, mostly genitourinary complaints. Due to the inherent breast cancer risk, estrogen-based therapies are generally avoided in these patients. So far, the non-hormonal approaches available are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
